Skip to main content
. 2020 Mar 24;11:351. doi: 10.3389/fphar.2020.00351

Table 3.

Registered clinical trials of herbs and natural products on fatty liver diseases (Referred to http://www.ClinicalTrials.gov website).

NCT number Status Conditions Interventions Outcome Measures Population Dates
NCT02030977 Completed NAFLD Resveratrol ALT Enrollment: 50 Age: 18 Years to 80 Years (Adult, Older Adult) Sex: All Study Start: June 2012 Study Completion: March 2013
NCT01464801 Completed Fatty liver Resveratrol

  • Change in hepatic steatosis and inflammation

  • Assessment of tolerability and side-effects

 Enrollment: 28 Age: 18 Years to 70 Years (Adult, Older Adult) Sex: All Study Start: September 2011 Study Completion: June 2015
NCT01446276 Completed Obesity

  • NAFLD

 Resveratrol

  • Hepatic VLDL-TG secretion and peripheral VLDL-TG clearance

  • Basal and insulin stimulated free fatty acid (FFA) and glucose turnover

  • VLDL-TG oxidation

  • Body composition (fat mass, fat-free mass, percent fat, visceral fat mass)

  • lipoprotein lipase activity and fat cell size in abdominal and femoral adipose tissue biopsy

  • Baseline data

 Enrollment: 26 Age: 25 Years to 65 Years (Adult, Older Adult) Sex: Male Study Start: November 2011 Study Completion: April 2014
NCT04130321 Not yet recruiting

  • Overweight

  • Microtia

  • Endotoxemia

  • Metabolic Syndrome

  • Insulin Resistance

  • NAFLD

 Camu camu (Myrciaria dubia)

  • Change in Gut Microbiota Composition and Diversity

  • Change in fat accumulation in the liver

  • Change in Endotoxemia

  • Change in Intestinal permeability

  • Change in Inflammation state of the tissue

  • Change in Short chain and branched chain fatty acids in the feces

  • Change in gut health

  • Change in stool consistency

  • Change in Glucose homeostasis

  • Change in Lipid profile and 8 more

 Enrollment: 32 Age: 18 Years to 75 Years (Adult, Older Adult) Sex: All Study Start: January 6, 2020 Study Completion: June 30, 2022
NCT0394512 Completed Liver Dysfunction Red ginseng Liver enzyme Enrollment: 94 Age: 37 Years to 63 Years (Adult) Sex: All Study Start: January 1, 2018 Study Completion: December 31, 2018
NCT03260543 Completed NAFLD Fermented ginseng powder Changes of ALT

  • Changes of Liver function index

  • Changes of fatty liver grade

  • Changes of lipid metabolism index

  • Changes of total antioxidant capacity

  • Changes of imflammation index

  • Changes of Multidimensional Fatigue Scale

 Enrollment: 90 Age: 19 Years to 70 Years (Adult, Older Adult) Sex: All Study Start: July 2016 Study Completion: August 2017
NCT04049396 Completed NAFLD Berberine ALT; AST; ALP; fasting blood sugar; total cholesterol; LDL-Cholesterol; HDL - Cholesterol; TG Enrollment: 50 Age: 18 Years to 65 Years (Adult, Older Adult) Sex: All Study Start: October 1, 2018 Study Completion: June 15, 2019
NCT02535195 Completed

  • NAFLD

 Ginger

  • Serum levels of the ALT liver enzyme

  • Serum levels of the AST liver enzyme

  • controlled attenuation parameter(CAP) score

 Enrollment: 60 Age: 18 Years to 70 Years (Adult, Older Adult) Sex: All Study Start: March 2013 Study Completion: August 2015
NCT02289235 Enrolling by invitation

  • Fatty Liver

  • Diabetes Mellitus, Type 2

 Ginger

  • Change in ALT level

  • Change in AST level

  • Change in score of fatty liver in fibroscan

  • Change in Gama GT (#- glutamyl transpeptidase) levels

  • Number of patients with adverse events

 Enrollment: 90 Age: 20 Years to 65 Years (Adult, Older Adult) Sex: All Study Start: November 1, 2018 Study Completion: December 1, 2019
NCT03864783 Recruiting

  • NAFLD

  • Insulin Resistance

  • Glucose Tolerance Impaired

  • Obesity, Abdominal

 Curcumin (Meriva®)

  • Curcumin’s effect on steatosis

  • Total amino acids in plasma

  • Total amino acids in plasma

  • Curcumin’s effect on plasma concentration of urea

  • Curcumin’s effect on urin concentration of urea

  • Curcumin’s effect on serum concentration of inflammatory marker interleukin (IL)-1b

  • Curcumin’s effect on serum concentration of inflammatory marker IL-2

  • Curcumin’s effect on serum concentration of inflammatory marker IL-6

  • Curcumin’s effect on serum concentration of inflammatory marker IL-10

  • Curcumin’s effect on serumconcentration of inflammatory marker tumor necrosis factor (TNF)- alpha

  • Curcumin’s effect on plasma concentration of adipokines

  • and 34 more

 Enrollment: 40 Age: 20 Years and older (Adult, Older Adult) Sex: Male Study Start: March 5, 2019 Study Completion: October 2020
NCT03073343 Recruiting Non-Alcoholic Fatty Liver Disease

  • Non Insulin Dependent Diabetes

  • ALT

 Betaine

  • ALT

 Enrollment: 48 Age: 18 Years to 75 Years (Adult, Older Adult) Sex: All Study Start: November 12, 2013 Study Completion: June 30, 2020
NCT02973295 Recruiting NAFLD Silymarin

  • Change (Reduction)

  • of parameters of liver steatosis defined by CAP (Controlled Attenuation Parameter) and liver fibrosis defined by

  • LSM (liver stiffness measurements) during the 6 months period

  • Change in liver enzymes in period of 6 months

  • Change in insulin resistance in period of 6 months

  • Change in lipidogram in period of 6 months

 Enrollment: 400 Age: 18 Years to 70 Years (Adult, Older Adult) Sex: All Study Start: September 20, 2019 Study Completion: June 30, 2021
NCT02929901 Completed Type 2 Diabetes Nonalcoholic Fatty Liver Caffeine and chlorogenic acid

  • Hepatic steatosis

  • Glucose

  • Glycated hemoglobin (HBA1C)

  • ALT

  • AST

  • hs- CRP)

  • gut microbiota

 Enrollment: 200 Age: 30 Years to 65 Years (Adult, Older Adult) Sex: All Study Start: December 2016 Study Completion: March 2019
NCT02908152 Unknown status

  • Type 2 Diabetes

  • Nonalcoholic Fatty Liver

 Curcumin

  • Hepatic steatosis

  • Glucose

  • HBA1C

  • ALT

  • AST

 Enrollment: 50 Age: 30 Years to 65 Years (Adult, Older Adult) Sex: All Study Start: February 2017 Study Completion: October 2017
NCT02006498 Completed NAFLD Sillymarin

  • To assess the efficacy

  • of Silymarin as defined by an improvement in non-alcoholic steatosis (NAS) activity score by at least 30% from baseline compared to placebo

  • To assess the safety and adverse event profile of Silymarin compared to placebo

 Enrollment: 99 Age: 18 Years and older (Adult, Older Adult) Sex: All Study Start: June 2012 Study Completion: December 2015
NCT01940263 Completed NAFLD Anthocyanin

  • Biomarkers related to oxidative stress

  • Biomarkers related to inflammation

 Enrollment: 63 Age: 18 Years to 65 Years (Adult, Older Adult) Sex: All Study Start: June 2013 Study Completion: June 2014
NCT02307344 Unknown status

  • Nonalcoholic Steatohepatitis

  • Liver Steatosis

 Nigella sativa L.

  • Effect of Nigella Sativa on Liver Triglyceride Concentration

  • Effect of Nigella Sativa on Improvement in NASH Activity Index

  • Effect of Nigella Sativa on Fibrosis Staging

 Enrollment: 100 Age: 18 Years and older (Adult, Older Adult) Sex: All Study Start: January 2015 Study Completion: January 2017
NCT02303314 Completed NAFLD Trigonella Foenum-graecum Seed Extract Liver stiffness change Enrollment: 35 Age: 18 Years to 70 Years (Adult, Older Adult) Sex: All Study Start: November 2014 Study Completion: September 2017
NCT01707914 Completed NAFLD Chinese bayberry juice (Myrica rubra) Plasma lipids profile Enrollment: 44 Age: 18 Years to 25 Years (Adult) Sex: All Study Start: June 2012
NCT01677325 Completed NAFLD Drug: Chinese herb (YiQiSanJu) (Angelica sinensis, Rehmannia, Cinnamomum cassia, Glycyrrhiza uralensis, Eucommia ulmoides, Achyranthes bidentate, Lycium chinense)

  • The CT ratio of liver/spleen

  • BMI(Body Mass Index)

  • liver function

  • lipid profile

  • NEFA

  • HOMA index

  • adiponectin

  • IL-6

  • hs-CRP (C-reactive protein)

  • TNF-a

  • leptin

 Enrollment: 40 Age: 18 Years to 65 Years (Adult, Older Adult) Sex: Male Study Start: January 2007 Study Completion: January 2008
NCT01210989 Completed NAFLD Phyllanthus urinaria L.

  • Histologic NAFLD activity score

  • ALT normalization

  • Metabolic endpoints

  • Changes in magnetic resonance spectroscopy

  • Liver stiffness measurement

  • Biomarkers of NASH and liver fibrosis

 Enrollment: 60 Age: 18 Years to 70 Years (Adult, Older Adult) Sex: All Study Start: May 2010 Study Completion: May 2012
NCT00816465 Completed NAFLD Hoodia gordonii (Masson) Sweet ex Decne.

  • Decreased insulin resistance

  • Safety

  • Reduced hepatic injury

  • Reduced weight/BMI/abdominal circumference

 Enrollment: 20 Age: 18 Years to 65 Years (Adult, Older Adult) Sex: All Study Start: May 2009 Study Completion: August 2010